These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31628143)

  • 1. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.
    Soliman PT; Westin SN; Iglesias DA; Fellman BM; Yuan Y; Zhang Q; Yates MS; Broaddus RR; Slomovitz BM; Lu KH; Coleman RL
    Clin Cancer Res; 2020 Feb; 26(3):581-587. PubMed ID: 31628143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
    Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
    J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
    Slomovitz BM; Filiaci VL; Walker JL; Taub MC; Finkelstein KA; Moroney JW; Fleury AC; Muller CY; Holman LL; Copeland LJ; Miller DS; Coleman RL
    Gynecol Oncol; 2022 Mar; 164(3):481-491. PubMed ID: 35063278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial.
    Fan Y; Sun T; Shao Z; Zhang Q; Ouyang Q; Tong Z; Wang S; Luo Y; Teng Y; Wang X; Wang S; Liu Q; Feng J; Shen K; Song Y; Wang J; Ma F; Li Q; Zhang P; Xu B
    JAMA Oncol; 2021 Oct; 7(10):e213428. PubMed ID: 34436536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
    El Dika I; Mayer RJ; Venook AP; Capanu M; LaQuaglia MP; Kobos R; O'Neill AF; Chou JF; Ly M; Ang C; O'Reilly EM; Gordan JD; Abou-Alfa GK
    Oncologist; 2020 Nov; 25(11):925-e1603. PubMed ID: 32400000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
    Slomovitz BM; Lu KH; Johnston T; Coleman RL; Munsell M; Broaddus RR; Walker C; Ramondetta LM; Burke TW; Gershenson DM; Wolf J
    Cancer; 2010 Dec; 116(23):5415-9. PubMed ID: 20681032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
    Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
    Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors.
    Ballhausen A; Wheler JJ; Karp DD; Piha-Paul SA; Fu S; Pant S; Tsimberidou AM; Hong DS; Subbiah V; Holley VR; Huang HJ; Brewster AM; Koenig KB; Ibrahim NK; Meric-Bernstam F; Janku F
    Clin Cancer Res; 2021 Mar; 27(5):1247-1255. PubMed ID: 33115815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
    van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
    Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
    Konstantinopoulos PA; Lee EK; Xiong N; Krasner C; Campos S; Kolin DL; Liu JF; Horowitz N; Wright AA; Bouberhan S; Penson RT; Yeku O; Bowes B; Needham H; Hayes M; Sawyer H; Polak M; Shea M; Cheng SC; Castro C; Matulonis UA
    J Clin Oncol; 2023 Jan; 41(3):599-608. PubMed ID: 36174113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
    Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
    Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.